Clinical research on detection of epidermal growth factor receptor gene mutations in a variety of lung tumors

Objective To investigate the epidermal growth factor receptor (EGFR) gene mutations in a variety of lung tumors and its clinical significance.Methods The clinical data of 60 cases of lung cancer patients admitted to our hospital during June 2006 to June 2012 were retrospectively analyzed,and then we applied the EGFR mutations digested enriched PCR method of plasma free nucleic EGFR exon-19 deletion and exon-21 L858R mutation.Patients with plasma EGFR gene mutation,sex,smoking history,TNM stage,pathological type and gefitinib treatment objective relationship between efficiency and disease progression-free were analyzed.Results (1) The group of 60 patients,plasma samples were detected and discovered the EGFR gene mutations were 29 cases,the mutation rate was 48.3%,and the plasma EGFR gene mutations occurred in lung adenocarcinoma patients (P0.01) as well as non-smoking patients (P0.01);(2) There was a statistically significant difference between the EGFR level of plasma and EGFR level of benign pulmonary disease (P0.01),and there was a significant difference between lung squamous cell lung adenosquamous carcinoma and mast cell cancer of plasma in EGFR levels (P0.05);(3) In the group of 34 patients received gefitinib treatment in patients with plasma EGFR gene mutation-positive patients objective efficiency with a median disease progression-free survival were significantly higher than plasma EGFR gene mutation-negative patients (P0.01).Conclusions EGFR gene mutations in a variety of lung tumor rate is nearly 50%,and plasma free nucleic acid digestion enriched PCR method can sensitively detect specific mutations in the EGFR gene and gene mutation detection positive patients on gefitinib reaction rate to be significantly higher than those of the wild-type patients.